Free Fatty Acid Receptor (FFAR)

AS2034178 free base is a specific agonist of the Free Fatty Acid Receptor 1 (GPR40). This compound has been demonstrated to enhance glucose-dependent insulin secretion, making it a valuable tool for investigating mechanisms underlying type 2 diabetes mellitus. Its oral bioactivity suggests potential applicability in therapeutic research aimed at metabolic disorders.

FFA1 agonist-1 is a potent agonist of fatty acid receptor 1 (FFA1), exhibiting an EC50 of 0.75 μM. This compound is designed for research applications related to type 2 diabetes mellitus, where modulation of FFA1 can influence metabolic pathways and insulin sensitivity. FFA1 agonist-1 provides a valuable tool for investigating the therapeutic potential of targeting this receptor in metabolic disorders.

Metabolex-36 is a potent agonist of the free fatty acid receptor 4 (FFA4), demonstrating a pEC50 value of 5.9. In contrast, it exhibits a significantly lower activity for FFA1, with a pEC50 value of less than 4.0. This compound is crucial for studies focused on metabolic regulation and the modulation of inflammatory pathways, making it a valuable tool in research related to obesity, diabetes, and cardiovascular diseases.

LY2922083 is a potent agonist of the free fatty acid receptor GPR40. This compound activates GPR40 in response to increased blood glucose levels, demonstrating potential as a glucose-lowering agent. Its biological activity makes it a valuable tool for research in metabolic diseases and insulin signaling pathways.

GPR40 Agonist 2 is an agonist of the free fatty acid receptor GPR40, playing a crucial role in glucose metabolism and insulin secretion. This compound is primarily utilized in diabetes research, providing insights into the regulatory mechanisms of energy homeostasis and metabolic disorders. Its activation of GPR40 has potential therapeutic implications for the management of type 2 diabetes and related metabolic diseases.